CompletedPhase 3NCT01191801
Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML
Studying Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sunesis Pharmaceuticals
- Principal Investigator
- Linda Neuman, MDSunesis Pharmaceuticals
- Intervention
- vosaroxin + cytarabine(drug)
- Enrollment
- 711 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2010 – 2017
Study locations (30)
- Moores UCSD Cancer Center, La Jolla, California, United States
- UCLA Division of Hematology/Oncology, Los Angeles, California, United States
- Sharp Clinical Oncology Research, San Diego, California, United States
- University of California San Francisco, San Francisco, California, United States
- HCA HealthONE - Rocky Mountain Blood and Marrow Transplant Program, Denver, Colorado, United States
- George Washington University-Medical Faculty Associates, Washington D.C., District of Columbia, United States
- Holy Cross Hospital, Fort Lauderdale, Florida, United States
- Baptist Cancer Institute, Jacksonville, Florida, United States
- H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
- Georgia Health Sciences University, Augusta, Georgia, United States
- Rush University Medical Center, Division of Hematology/Oncology, Chicago, Illinois, United States
- University of Chicago, Chicago, Illinois, United States
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
- St. Francis Medical Group Oncology and Hematology Specialists, Indianapolis, Indiana, United States
- University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01191801 on ClinicalTrials.govOther trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06303193Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative NeoplasmsNational Cancer Institute (NCI)
- RECRUITINGPHASE3NCT07422480A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood TransfusionsTakeda
- RECRUITINGNANCT07500753A Single-arm, Prospective Study of a Cladribine-Bridged LABU Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory MDS/AML in Elderly PatientsThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE4NCT07486713Olutasidenib DDI Study in Patients With IDH1 Mutation Positive MalignanciesRigel Pharmaceuticals
- RECRUITINGPHASE1NCT07107126Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic SyndromesRemedy Plan, Inc.
- RECRUITINGPHASE1NCT07270978Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDSUniversity of Virginia
- RECRUITINGNANCT06781099Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or MyelofibrosisHospices Civils de Lyon
- RECRUITINGPHASE2NCT07228273Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid LeukemiaOHSU Knight Cancer Institute